Bank of New York Mellon Corp Has $83.72 Million Stock Holdings in Encompass Health Corporation $EHC

Bank of New York Mellon Corp decreased its stake in Encompass Health Corporation (NYSE:EHC) by 2.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 865,542 shares of the company’s stock after selling 20,789 shares during the period. Bank of New York Mellon Corp’s holdings in Encompass Health were worth $83,724,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Northwestern Mutual Wealth Management Co. increased its holdings in shares of Encompass Health by 3,059,159.7% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 3,793,482 shares of the company’s stock worth $402,640,000 after buying an additional 3,793,358 shares in the last quarter. Norges Bank acquired a new stake in shares of Encompass Health during the 4th quarter valued at $133,221,000. Price T Rowe Associates Inc. MD grew its position in Encompass Health by 24.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,805,413 shares of the company’s stock worth $510,047,000 after acquiring an additional 948,202 shares during the last quarter. Millennium Management LLC increased its holdings in Encompass Health by 140.0% in the 3rd quarter. Millennium Management LLC now owns 1,223,665 shares of the company’s stock worth $155,430,000 after purchasing an additional 713,738 shares in the last quarter. Finally, 8 Knots Management LLC bought a new position in Encompass Health in the second quarter valued at about $78,644,000. Institutional investors own 97.25% of the company’s stock.

Encompass Health Trading Down 0.6%

NYSE EHC opened at $111.87 on Wednesday. The firm has a market capitalization of $11.10 billion, a PE ratio of 18.68, a price-to-earnings-growth ratio of 2.45 and a beta of 0.74. The business’s 50-day moving average price is $104.70 and its two-hundred day moving average price is $103.67. The company has a current ratio of 1.17, a quick ratio of 1.17 and a debt-to-equity ratio of 0.76. Encompass Health Corporation has a 12 month low of $92.77 and a 12 month high of $127.99.

Encompass Health (NYSE:EHC) last posted its quarterly earnings data on Thursday, April 30th. The company reported $1.60 EPS for the quarter, topping analysts’ consensus estimates of $1.51 by $0.09. Encompass Health had a return on equity of 18.28% and a net margin of 10.04%.The company had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.57 billion. During the same period in the previous year, the firm earned $1.37 earnings per share. The firm’s quarterly revenue was up 9.0% on a year-over-year basis. Encompass Health has set its FY 2026 guidance at 5.890-6.110 EPS. On average, analysts expect that Encompass Health Corporation will post 5.97 EPS for the current year.

Encompass Health Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, July 15th. Stockholders of record on Wednesday, July 1st were given a $0.19 dividend. The ex-dividend date was Wednesday, July 1st. This represents a $0.76 dividend on an annualized basis and a dividend yield of 0.7%. Encompass Health’s payout ratio is 12.69%.

Insider Activity at Encompass Health

In other news, EVP Patrick William Tuer sold 682 shares of the stock in a transaction on Monday, May 11th. The shares were sold at an average price of $104.56, for a total transaction of $71,309.92. Following the completion of the sale, the executive vice president directly owned 24,755 shares in the company, valued at $2,588,382.80. This represents a 2.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 1.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on EHC. TD Cowen assumed coverage on Encompass Health in a report on Thursday, May 28th. They set a “buy” rating and a $125.00 price target on the stock. Weiss Ratings lowered shares of Encompass Health from a “buy (b-)” rating to a “hold (c+)” rating in a report on Friday, June 26th. Leerink Partners set a $152.00 target price on shares of Encompass Health in a report on Friday, May 22nd. Wall Street Zen upgraded shares of Encompass Health from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Finally, Barclays dropped their price target on shares of Encompass Health from $153.00 to $140.00 and set an “overweight” rating for the company in a research note on Tuesday, May 5th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $143.86.

Encompass Health Profile

Encompass Health Corporation is a leading provider of post‐acute healthcare services in the United States, operating a comprehensive network of inpatient rehabilitation hospitals and home health and hospice agencies. Its inpatient rehabilitation hospitals offer intensive therapy programs for patients recovering from conditions such as stroke, brain injury, spinal cord injury, cardiac and pulmonary disorders, and orthopedic procedures. Through its home health segment, Encompass Health delivers skilled nursing, physical therapy, occupational therapy and speech therapy to patients in the comfort of their homes, while its hospice services provide end‐of‐life care focused on symptom management and emotional support for patients and families.

Founded in 1984 as HealthSouth Corporation and rebranded as Encompass Health in 2018, the company has grown organically and through acquisitions to serve patients across more than 30 states.